Clinical Trials for Mesothelioma Patients: NGR-hTNF as Single Agent
Read about a current clinical trial being conducted to study NGR-hTNF as a single agent in patients who have been diagnosed with mesothelioma. At this time, the study is only being conducted in Italy. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma (NGR010)
Purpose:
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent.
Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.
Requisite Conditions:Mesothelioma
Intervention:
Drug: NGR-hTNF
Study Phase, Type and Design:
Phase II Interventional; Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study
Official Title:
NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen
If you or a loved one has been doagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.
Clinical trial of NGR-hTNF as a single agent in mesothelioma patients